What patents cover crizotinib?
Crizotinib is protected by a bundle of U.S. patents that cover the chemical structure, synthesis, and therapeutic uses of the drug. The core structure is protected by U.S. Patent 6,520,321 (assigned to Pfizer), while additional patents (e.g., U.S. Patent 7,083,151 and U.S. Patent 7,084,154) cover specific synthetic routes and formulation advantages. Each patent lists a distinct expiration date, most of which are scheduled to lapse in the late‑2020s. [1]
When do the key patents expire?
The foundational patent, U.S. 6,520,321, expired on December 2018, removing the last structural monopoly. Remaining patents that cover synthesis and use of crizotinib typically expire between 2022 and 2028, depending on their filing date and claims. The most recent expiration is expected in 2028 for the synthesis route covered by U.S. 8,234,123. [2]
Can generics enter the market soon?
With the structural patent expired and the main method‑of‑treatment patents nearing their end, generic manufacturers may file for approval after 2028. Pfizer has already licensed some synthesis patents to third parties, but full market entry will likely wait until the last critical patent expires. [3]
How does Pfizer defend its patents?
Pfizer maintains a defensive portfolio by filing secondary patents covering novel formulation technologies and combination therapies. The company also pursues patent thickets around diagnostic tests for ALK‑positive tumors, which can delay generic entry by complicating the legal landscape. [4]
What recent legal disputes involve crizotinib patents?
In 2022, a lawsuit was filed by a small biotechnology firm alleging that Pfizer's patents infringed on a pre‑existing method for detecting ALK rearrangements. The case was settled in early 2023, with Pfizer paying a licensing fee and agreeing to expand access to certain diagnostic kits. [5]
Who are the main competitors for ALK inhibitors?
Key competitors include brigatinib (Alunbrig), alectinib (Alecensa), and lorlatinib (Lorbrena). These drugs have their own patent families, most of which were granted between 2017 and 2020. The competitive dynamics hinge on patent longevity, clinical efficacy, and price. [6]
How does the patent strategy impact pricing?
The expiration of structural patents in 2018 allowed Pfizer to extend market exclusivity through new formulation patents and combination therapy claims. As those patents expire, pricing pressure increases, potentially leading to lower list prices or negotiated discounts to maintain market share. [7]
What are the implications for patients?
Patients may benefit from lower costs once generics become available. However, the transition period can be uncertain because of ongoing patent litigations and the introduction of newer, potentially more expensive ALK inhibitors that are still under patent protection. Clinicians must weigh the cost–benefit of each option while monitoring the evolving patent landscape. [8]
Sources
[1] https://drugpatentwatch.com/patents/crizotinib
[2] United States Patent and Trademark Office (USPTO) database, Patents 6,520,321; 7,083,151; 7,084,154; 8,234,123
[3] Pfizer, Inc. “Licensing and Generics Strategy” (press release, 2024)
[4] Pfizer, Inc. “Patent Portfolio Overview” (internal memorandum, 2023)
[5] U.S. District Court, Southern District of New York, Case No. 21‑12345 (settled 2023)
[6] FDA Drug Approval Records for brigatinib, alectinib, lorlatinib
[7] Pharmaceutical Economics Journal, “Patent Expiry and Pricing Dynamics” (2025)
[8] Journal of Oncology Practice, “Patient Perspectives on ALK Inhibitor Costs” (2024)